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Summary
 
Tumor necrosis factor receptor (TNFR)–associated factor 2 (TRAF2) and TRAF1 were found
as components of the TNFR2 signaling complex, which exerts multiple biological effects on
cells such as cell proliferation, cytokine production, and cell death. In the TNFR2-mediated
signaling pathways, TRAF2 works as a mediator for activation signals such as NF-
 
k
 
B, but the
role of TRAF1 has not been previously determined. Here we show in transgenic mice that
TRAF1 overexpression inhibits antigen-induced apoptosis of CD8
 
1
 
 T lymphocytes. Our re-
sults demonstrate a biological role for TRAF1 as a regulator of apoptotic signals and also sup-
port the hypothesis that the combination of TRAF proteins in a given cell type determines dis-
tinct biological effects triggered by members of the TNF receptor superfamily.
 
A
 
ntigen-induced cell death of T cells plays a critical role
in the establishment of T cell tolerance and also in
feedback regulatory mechanisms of immune responses (1–6).
Members of the TNF receptor (TNFR)
 
1
 
 family are in-
volved in the regulation of antigen-induced cell death of
T cells (7, 8). Experiments with spontaneous mutant or
knock out mice have shown that Fas(CD95) and the two
TNF receptors (TNFR1 and TNFR2) participate in the
induction of apoptosis and subsequent deletion of antigen-
specific mature T cells (9–13). Progress has also been made
by showing that overexpression of various signal transduc-
ers can trigger cell death upon overexpression (14–19). Both
Fas(CD95) and TNFR1 contain conserved death domains
in their cytoplasmic tails, which mediate defined protein–
protein interactions (20, 21), allowing the recruitment of
other death domain–containing proteins such as FADD
(MORT1), TRADD, or RIP (14–19). The association of
FADD to Fas(CD95) or TNFR1 results in the recruitment
of FLICE/MACH, the activation of which in turn leads to
cell death (22, 23). In contrast with Fas(CD95) or TNFR1,
the cytoplasmic tail of TNFR2 does not contain a death
domain and does not interact with death domain contain-
ing proteins such as FADD, RIP or TRADD, suggesting
that other signaling molecules mediate the induction of cell
death by this receptor.
The cytoplasmic tail of TNFR2 has been shown to in-
teract with signal transduction molecules known as TRAF
proteins (TRAF1 and TRAF2) (24). Six members of the
TRAF family have been identified that interact with vari-
ous members of the TNFR superfamily (24–33). In some
cases, TRAF proteins have been shown to mediate various
biological effects exerted by their cognate receptors. For
example, TRAF2 was shown to mediate NF-
 
k
 
B activation
induced by TNFR2 and by several other members of the
TNFR superfamily (18, 34–36). This was determined by
experiments based on a transient transfection assay system
in vitro. However, the biological role of TRAF1 in the
TNFR2 signaling complex was not revealed by similar in
vitro transfection experiments, although it has been impli-
cated as an adapter protein (37). TRAF1 is associated with
various members of the TNFR superfamily that exert mul-
tiple effects on cells, and TRAF1 mRNA expression can
only be detected in limited tissues such as spleen, lung, and
testis (24). Therefore, it is likely that TRAF1 mediates
some functions other than NF-
 
k
 
B activation, which can-
not be elucidated by experiments based on transient trans-
fection in vitro.
In this report, we describe that antigen-induced deletion
of mature CD8
 
1
 
 T cells are hampered in transgenic mice
overexpressing TRAF1. Induction of TCR-mediated apop-
tosis of purified T cells from TRAF1 transgenic mice was
also inhibited, suggesting that TRAF1 overexpression affected
 
1
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the signals required for induction of apoptosis in mature
CD8
 
1
 
 T cells. These results suggest that TRAF1 is involved
in the signal transduction pathway for antigen-induced apop-
tosis of T cells. The data in this report also provide evi-
dence for that different combinations of TRAF proteins
may mediate different signals such as cell proliferation or
apoptosis.
 
Materials and Methods
 
Generation of TRAF1 Transgenic Mice.
 
An expression vector
(pHSE–TRAF1) for TRAF1 transgenic mice was generated by
cloning the Flu epitope–tagged murine TRAF1 cDNA (32) into
5
 
9
 
 SalI–BamHI 3
 
9
 
 site of the pH SE-3
 
9
 
 expression cassette (38, 39).
pHSE-3
 
9
 
 expression cassette with an H-2K promoter and an IgH
enhancer was previously described to express the transgene both
in immature thymocytes and in mature T cells (38, 39). Trans-
gene DNA was isolated by XhoI digestion and microinjected into
(C57BL/6 
 
3
 
 CBA/J)F2 embryos. Transgenic founders were iden-
tified by Southern blot analysis of tail DNA and transgenic lines
were established by backcrossing with either C57BL/6 or BALB/c
mice to yield vSAG7
 
2
 
 H-2
 
b/b
 
 or H-2
 
d/b
 
 mice.
 
Mice and Reagents.
 
Mice transgenic for an 
 
ab
 
TCR specific
for H-2D
 
b
 
 and the lymphocyte choriomeningitis virus (LCMV) gly-
coprotein (GP)–derived peptide amino acids 33–41 (GP33, the ma-
jor LCMV epitope in the H-2
 
b
 
 haplotype) were previously described
(13, 38, 39)and crossed with TRAF1 transgenic mice. The peptide
GP33 (KAVYNFATM) was synthesized as described (13). mAbs, rat
anti-CD8 (53-6.7; FITC conjugated), and anti-Va2 (B20.1; PE
conjugated) were purchased from PharMingen (San Diego, CA).
 
Induction of Apoptosis and Lymphocyte Survival Assays.
 
For induc-
tion of apoptosis in vitro, lymph node T cells from TRAF1 trans-
genic and negative littermates were treated with Con A (5 
 
m
 
g/ml)
for 48 h, washed with 10 mg/ml 
 
a
 
-methylmannoside, and incu-
bated in 50 IU/ml IL-2 to predispose to apoptosis as previously
described (12). Cells (50,000/well) with 
 
.
 
97% 
 
ab
 
-TCR
 
1
 
 were
then cultured for 48 h in anti-CD3
 
e
 
 Ab (145-2C11)–coated
plates in triplicate. Viable cells were then quantified by propidium
iodide (PI) exclusion using a FACSCaliber
 
Ò
 
 with CELLQUEST
software. Viable cells show low PI fluorescence. Specific cell sur-
vival (%) was determined from the percentages of viable (PI-neg-
ative) cells and it equals 100 
 
3
 
 (% survival after CD3 cross-link-
ing / % survival without CD3 cross-linking).
To induce apoptosis of antigen-specific T cells in TCR trans-
genic mice, mice were treated with a single intrafootpad injection
of GP33 peptide (30 
 
m
 
g). TCR transgenic CD8
 
1
 
 cells from TRAF1
transgenic mice and negative littermates in regional lymph nodes
were analyzed 3 and 4 d after intrafootpad injection of GP33 pep-
tide. Draining popliteal and inguinal lymph node cells were taken
from TCR transgenic mice (H-2
 
b
 
) either untreated (day 0) or 2 d
after a single intrafootpad injection of 30 
 
m
 
g GP33 peptide and
incubated in IMDM supplemented with 10% FCS, 5 
 
3
 
 10
 
2
 
5
 
 M
2-mercaptoethanol, penicillin, and streptomycin (complete IMDM)
for 24 h (day 3) or 48 h (day 4) as described (13). The percentages
of surviving cells were determined by flow cytometry (FACS-
can
 
Ò
 
) by gating for lymphocytes based on forward and side scatter.
For induction of tolerance by high dose peptide antigens in
non-TCR transgenic mice, H-2
 
b
 
 TRAF1 transgenic or negative
littermates were injected intraperitoneally on days 0, 3, and 6
with 500 
 
m
 
g GP33 peptide or buffered salt solution in IFA as pre-
viously described (40, 41). The mice were infected on day 16 and
tested on day 24 as previously described (41, 42).
For induction of apoptosis by LCMV, 10
 
6
 
 TCR transgenic
spleen cells from TRAF1/TCR double-transgenic or TCR sin-
gle-transgenic littermates were injected intravenously in C57BL/6
mice as previously described (42). At the same time, the mice
were infected with LCMV WE strain. For in vivo expansion, the
viral dose was 200 PFU and analysis was 7 d after infection; for in
vivo deletion, the viral dose was 10
 
6
 
 PFU and analysis was 4 and
7 d after infection. TCR transgenic T cells were determined by
double staining with CD8- and V
 
a
 
2-specific antibodies and flow
cytometry analysis by gating for lymphocytes based on forward/
side scatters.
 
Lymphocyte Proliferation and Cytotoxicity Assay.
 
T cells isolated
from lymph nodes using T cell enrichment columns (Biotex Lab-
oratories, Inc., Edmonton, Canada) were also induced to prolifer-
ate by titrating them in triplicate into anti-TCR Ab (H57-597)
coated tissue culture wells containing mitomycin C–treated sple-
nocytes (5 
 
3
 
 10
 
5
 
/well) as previously described (43). [
 
3
 
H]thymi-
dine was added 3 d later for 8–12 h. The culture was harvested
and analyzed as previously described (43).
Responder spleen cells (10
 
5
 
/well) from TRAF1/TCR double-
transgenic or TCR single-transgenic littermates were cultured
with 2 
 
3
 
 10
 
4
 
 20 Gy-irradiated stimulator macrophages previously
labeled with 10 nM GP33 in 96-well flat-bottomed microtiter
plates at 37
 
8
 
C, 5% CO
 
2
 
 in complete IMDM. After 3 d, the cul-
tures were pulsed for 16 h with 1 
 
m
 
Ci of [
 
3
 
H]thymidine, har-
vested, and counted on a Matrix 96 direct 
 
b
 
 counter (Canberra
Packard). The data are expressed as mean cpm of triplicate cul-
tures. Cytotoxicity by TCR transgenic spleen cells was tested in
duplicate cultures and serial dilutions in 96-well round-bottomed
Figure 1. Transgenic mice overexpressing TRAF1. (A) Northern blot
analysis of TRAF1 expression. Total RNA was isolated from thymocytes
and splenocytes, and analyzed by Northern blot analysis using a TRAF1
cDNA probe as previously described (32). TRAF1 mRNA is indicated by
an arrow. The amount of total RNA loaded in each lane was similar
based on the EtBr-stained rRNAs (data not shown). Upon longer expo-
sure of the autoradiogram, low level of TRAF1 mRNA was detected
both in thymocytes and splenocytes from control mice (data not shown).
(B) Western blot analysis of TRAF1 protein expression. Cell lysates were
purified from thymocytes and splenocytes, and analyzed by Western blot
analysis using an anti-epitope mAb (12CA5) as previously described (32).
Flu epitope–tagged TRAF1 protein is indicated by an arrow. Western
blot analysis with anti-TRAF1 polyclonal Abs showed similar results (data
not shown). 
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plates in 5-h 
 
51
 
Cr (NEN DuPont, Boston, MA) release assays using
EL4 target cells (H-2
 
b
 
) previously incubated with 10 nM GP33
peptide for 1 h at 37
 
8
 
C. The supernatant of the cytotoxicity cul-
tures was counted by a Cobra II Gamma Counter (Canberra Packard).
 
Results and Discussion
 
To examine the potential role of TRAF1 during anti-
gen-induced deletion of mature T cells that are mediated in
part by TNFRs, we have generated transgenic mice that
overexpress TRAF1 in various subsets of T cells. Levels of
TRAF1 expression in thymus or spleen from TRAF1 trans-
genic mice exceeded those seen in control animals by 5- to
20-fold when determined by Northern or Western blot
analysis (Fig. 1, 
 
A
 
 and 
 
B
 
). Two of these transgenic lines
(TRAF1.TG-11 and TRAF1.TG-10) were used for fur-
ther analysis.
The TRAF1 transgenic mice revealed no gross anatomi-
cal abnormalities. Flow cytometry analysis of thymocytes
from 6- to 8-wk-old TRAF1 transgenic or negative litter-
mates did not indicate any significant difference in the total
number of thymocytes (data not shown). Moreover, the
percentage of double-negative (CD4
 
2
 
CD8
 
2
 
), double-pos-
itive (CD4
 
1
 
CD8
 
1
 
), and single-positive (CD4
 
1
 
 or CD8
 
1
 
)
thymocytes in TRAF1 transgenic mice was comparable to
that in negative littermates (data not shown). The numbers
and ratios of T and B cells or CD4
 
1
 
 and CD8
 
1
 
 T cells
from spleen or lymph nodes of TRAF1 transgenic mice
were also comparable to those in negative littermates (data
not shown), suggesting that TRAF1 overexpression did not
dramatically affect lymphocyte development. When purified
T cells from TRAF1 transgenic and negative littermates were
tested for their ability to divide in response to anti-TCR
antibody (H57-597) in vitro, T cells from TRAF1 trans-
genic and negative littermates responded similarly to anti-
TCR Ab (Fig. 2 
 
A
 
). These results demonstrate that TRAF1
overexpression did not affect TCR-mediated proliferation
of mature T cells in vitro.
To examine whether TCR-mediated mature T cell death
from TRAF1 transgenic mice was affected in vitro, resting
lymph node cells from TRAF1 transgenic and negative lit-
termates were primed for apoptosis by Con A and IL-2
 
Figure 2.
 
In vitro proliferation and apoptosis of mature T cells. (
 
A
 
)
TRAF1 overexpression does not affect TCR-mediated proliferation of
mature T cells in vitro. T cells were isolated from lymph nodes of control
(
 
open circle
 
) and TRAF1.TG-10 transgenic (
 
closed circle
 
) littermates using
T cell enrichment columns (Biotex Laboratories, Inc.) and cultured in tripli-
cate into anti-TCR Ab (H57-597) coated-tissue culture wells containing
mitomycin C–treated splenocytes (5 
 
3
 
 10
 
5
 
/well). [
 
3
 
H]thymidine was
added 3 d later for 8–12 h. The culture was harvested and analyzed as de-
scribed in Materials and Methods. The data show the mean cpm 
 
6
 
 SEM
from the triplicate samples. The data are from one of several similar ex-
periments using T cells from nontransgenic and TRAF1.TG-10 trans-
genic mice littermates (H-2
 
d/b
 
). Similar results were obtained when T
cells from TRAF1.TG-11 mice were used (data not shown). (
 
B
 
 and 
 
C
 
)
TRAF1 overexpression inhibits TCR-mediated apoptosis of CD8
 
1
 
 T
 
cells in vitro. A representative experiment showing the flow cytometric
plots displaying propidium iodide (PI) fluorescence versus forward light
scatter for TRAF1 transgenic and negative littermates after 48 h with IL-2
in either uncoated wells (medium) or wells coated with anti-CD3
 
e
 
 (10
 
m
 
g/ml) is shown in 
 
B.
 
 Viable cells were quantified by PI exclusion using
a FACSCaliber
 
Ò
 
 with CELLQUEST software and show low PI fluores-
cence. Percent of total cells in each region is indicated. In 
 
C
 
, the per-
centages of cell survival in CD8
 
2
 
 (CD4
 
1
 
) or CD8
 
1
 
 T cells were shown
as the mean 
 
6
 
 SEM from the triplicate samples of three mice from each
group. Cells, cultured in either uncoated (medium) or anti-CD3
 
e
 
–coated
plates as described in 
 
B
 
, were recovered from the plates and stained with
anti-CD8 Ab (53-6.7; FITC conjugated). The CD8 staining was used to
gate the cells into CD8
 
1
 
 and CD8
 
2
 
 pools; control staining showed that
virtually all CD8
 
2
 
 cells were CD4
 
1
 
. Specific cell survival (%) was deter-
mined from the percentages of viable (PI-negative) cells and it equals 100 
 
3
 
(% survival after CD3 cross-linking/% survival without CD3 cross-link-
ing). 
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treatment as previously described (12). When the TCR–
CD3 complex was cross-linked, T cells from control mice
underwent massive cell death as previously shown (12)
(Fig. 2 
 
B
 
). However, the percentage of T cells undergoing
anti-CD3–induced death from TRAF1.TG-10 mice was
significantly lower than that of T cells from negative litter-
mates (Fig. 2 
 
B
 
). Percent viable cells of CD8
 
1
 
 or CD8
 
2
 
(CD41) T cells as determined from PI-negative cells with
and without anti-CD3 stimulation showed a protective ef-
fect of TRAF1 for CD81 T cell death (Fig. 2 C). No such
effect was seen for CD82 (CD41) T cell death (Fig. 2 C).
Because the death of CD81 T cells in this in vitro experi-
mental system is mostly mediated by TNFR2 (12), the re-
sults strongly suggest that TRAF1 overexpression antago-
nized the apoptotic signals exerted by TNFR2. The results
showing that CD82 (CD41) T cell death was not affected by
TRAF1 overexpression indicates that TRAF1 overexpres-
sion specifically inhibited TCR-mediated mature CD81
T cell death at least in this in vitro deletion system. Unlike
the TRAF1.TG-10 mice, the death of T cells from TRAF1.
TG-11 mice triggered by the similar TCR–CD3 complex
cross-linking in vitro was similar to that of T cells from
control mice (data not shown). This is probably because of
the difference between these two transgenic lines in the
amount of TRAF1 expressed.
To examine further the effect of TRAF1 overexpression
on the induction of apoptosis of CD81 T cells, we have
examined the deletion of mature T cells in TRAF1 trans-
genic mice using a defined LCMV glycoprotein–specific
TCR model (38, 39). ab-TCR transgenic mouse line spe-
cific for H-2Db and LCMV GP (residues 33–41, GP33)
(38, 39) was bred with TRAF1 transgenic mice. Owing to
the high mortality of TRAF1.TG-10 mice with yet to be
determined reasons, only mice from the TRAF1.TG-11 line
were used in these experiments. Development and selec-
tion of LCMV-specific ab-TCRs in TCR–TRAF1 dou-
ble-transgenic mice was normal when compared with that
in control TCR single-transgenic littermates (data not shown).
When splenocytes from ab-TCR–TRAF1 double-trans-
genic mice were stimulated with GP33, the degree of prolif-
eration was comparable to splenocytes from ab-TCR
single-transgenic mice (Fig. 3 A). Moreover, CTLs from
ab-TCR–TRAF1 double-transgenic mice showed cytotox-
icity to target cells presenting GP33 peptides comparable to
ab-TCR single-transgenic mice (Fig. 3 B). These results
are consistent with earlier experiments (Fig. 2 A) and con-
firm that TRAF1 overexpression did not affect T cell de-
velopment, the proliferative response, or the effector function
of T cells.
To test whether TRAF1 overexpression affected the an-
tigen-induced apoptosis of mature T cells, 30 mg of GP33
peptides was injected into the hind footpad. This protocol
induces cell death of antigen-specific T cells in the draining
lymph nodes (13). When transgenic TCR1 T cells were
analyzed from the draining lymph nodes of TCR single-
transgenic mice, antigen-induced cell death of transgenic
TCR1 T cells was clearly observed after peptide treatment
as previously described (13) (Fig. 3 C). When T cells were
examined from the ab-TCR–TRAF1 double-transgenic
mice injected with GP33 peptide, the death of transgenic
TCR1 T cells was significantly reduced compared with
ab-TCR single-transgenic mice (Fig. 3 C). These results
suggested that TRAF1 overexpression hampered a signal-
Figure 3. Normal proliferation and CTL response, but impaired acti-
vation-induced cell death in TCR–TRAF1 double-transgenic mice. (A)
TRAF1 overexpression does not alter antigen-induced proliferation. Pro-
liferation of GP33 peptide-specific TCR transgenic lymphocytes from
TRAF1 transgenic mice (closed symbols) and negative littermates (open sym-
bols) in the presence of unlabeled macrophages (circles) or macrophages la-
beled with GP33 peptide (squares). (B) Normal virus-specific cytotoxic re-
sponses are induced in TRAF1 transgenic mice. Similar cytotoxicity to
EL4 target cells unlabeled (circles) or labeled with GP33 peptide (squares)
by TCR transgenic spleen cells stimulated for 2 d with GP33 in vitro:
TRAF1 transgenic mice (closed symbols) and negative littermates (open sym-
bols). Proliferation and cytotoxicity of transgenic T cells were determined
as described in Materials and Methods and one of three representative ex-
periments is shown. (C) Overexpression of TRAF1 inhibits activation-
induced cell death. Increased survival of TCR transgenic CD81 cells
from TRAF1 transgenic mice (closed symbols) as opposed to negative litter-
mates (open symbols) in regional lymph nodes analyzed 3 and 4 d after in-
trafootpad injection of GP33 peptide. Data are percent PI-negative (sur-
viving) cells in the CD81population. One of three representative
experiments is shown. (D) Normal expansion but impaired deletion of vi-
rus-induced CD81 T cells in vivo. 106 TCR transgenic spleen cells from
TRAF1–TCR double-transgenic (closed bars) or TCR single-transgenic
(open bars) littermates were injected intravenously in C57BL/6 mice as de-
scribed in Materials and Methods. At the same time, the mice were in-
fected with LCMV WE strain. For in vivo expansion, the viral dose was
200 PFU and analysis was 7 d after infection; for in vivo deletion, the vi-
ral dose was 106 PFU and analysis was 4 and 7 d after infection. The data
indicate percentages of spleen cells as determined by double staining with
CD8- and Va2-specific antibodies and flow cytometry analysis by gating
for lymphocytes based on forward/side scatters.1781 Speiser et al.
ing pathway required for the antigen-induced apoptosis of
CD81 T cells.
Additional experiments involving adoptive transfers of
transgenic TCR1 T cells along with antigen were per-
formed to determine the effect of TRAF1 overexpression
on the deletion of CD81 T cells. As previously shown,
when transgenic TCR1 T cells specific for LCMV GP33
were transferred to C57BL/6 mice with a high dose of
LCMV, a vigorous expansion of transgenic T cells was fol-
lowed by a rapid decline due to the induction of cell death
(42) (Fig. 3 D). When the same experiment was performed
with transgenic TCR1 T cells from TCR–TRAF1 dou-
ble-transgenic mice, the deletion of transgenic TCR1 T cells
was significantly lower (Fig. 3 D), indicating that TRAF1
overexpression inhibited the deletion of CD81 T cells in-
duced by high dose antigen treatment. Consistent with in
vitro proliferation experiments, TRAF1 overexpression did
not affect expansion of transgenic TCR1 T cells by a low
dose of LCMV during adoptive transfer (42) (Fig. 3 D).
TRAF1 overexpression also inhibited the induction of
tolerance to LCMV glycoprotein by high dose antigen
treatment in non-TCR transgenic mice. When mice were
infected with LCMV, both TRAF1 transgenic and nega-
tive littermates mounted an efficient CTL response (Fig. 4 A).
When control mice were pretreated three times intraperi-
toneally with 500 mg of GP33 in IFA, the induction of
CTL activities against LCMV was completely abrogated as
previously described (40, 41) (Fig. 4 B). In contrast, TRAF1
transgenic mice mounted significant LCMV-specific CTL
activities even after they were pretreated three times intra-
peritoneally with 500 mg GP33 in IFA (Fig. 4 C). These re-
sults indicate that TRAF1 overexpression did not affect
CTL activation but inhibited antigen-induced T cell death.
In contrast with the deletion of mature T cells induced
by a peptide antigen, TRAF1 overexpression did not in-
hibit superantigen-induced deletion of mature T cells. When
TRAF1 transgenic mice were treated three times intraperi-
toneally with 100 mg of staphyloccocal enterotoxin B (SEB),
the deletion of either CD41 or CD81 T cells from TRAF1
transgenic mice was comparable to that of T cells from con-
trol mice (data not shown). This suggests that TRAF1 over-
expression inhibits only specific signaling cascades required
for deletion of mature T cells in vivo, rather than acting as
a nonspecific anti-apoptotic signal. Complex and multiple
pathways were shown to operate in the induction of apop-
tosis in mature T cells. For example, the involvement of
Fas(CD95) has been shown for deletion of CD41 T cells in
the 2B4 TCR transgenic mice system but both Fas(CD95)
and TNFRs for deletion of CD41 T cells in the HNT
TCR transgenic mice system (10, 11). Therefore, it is pos-
sible that different experimental systems involving various
TCR–MHC–Ag complexes with different affinities/avid-
ities may result in the utilization of multiple pathways to
mediate cell death. This may explain why TRAF1 overex-
pression inhibits the induction of apoptosis in mature
CD81 T cells by a peptide antigen (i.e., GP33) but not by a
superantigen (SEB).
In summary, the results in this study showed that TRAF1
overexpression inhibits the antigen-induced deletion of ac-
tivated CD81 T cells in vivo and in vitro. Although we
have failed to show that TRAF1 overexpression did not af-
fect CD41 T cells, this does not exclude the possibility that
TRAF1 can play a role, which needs to be determined, in
CD41 T cell death in some experimental systems. Never-
theless, the results provide evidence for the biological role
of TRAF1 as a regulator of the antigen-induced apoptotic
signals in mature T cells.
TRAF1 is a component of the TNFR2 signaling com-
plex (24) and TRAF1 overexpression inhibited antigen-
induced apoptosis of mature CD81 T cells in an in vitro
system, in which anti-TCR–induced apoptosis of CD81
T cells is mediated by the TNFR2 signaling complex (12).
This suggests that the signal intermediates for induction
of apoptosis by the TNFR2 involves TRAF1. Whether
TNFR2-mediated signals can induce cell death has been
controversial due to various contradicting results (7, 8). Ex-
periments described here showing that the overexpression
of TRAF1, a TNFR2-proximal signaling component, in-
hibits the induction of apoptosis support the idea that prox-
imal signals induced by the TNFR2 are directly involved
in the TCR-mediated cell death of mature CD81 T cells.
The precise mechanism that TRAF1 overexpression in-
hibits the induction of apoptosis is not clear at this point.
Because TRAF1 (and also other TRAF proteins) does not
contain any known catalytic domain, it is most likely that
TRAF1 overexpression inhibited the TNFR2-mediated
apoptosis by altering the constituents of the TNFR2 signal-
ing complex. It has been recently shown that NF-kB acti-
vation acts as an anti-apoptotic signal during TNF-induced
Figure 4. TRAF1 overexpression inhibits peptide-induced T cell tol-
erance in vivo also in non-TCR transgenic mice. (A) The LCMV-spe-
cific cytotoxic responses are similar in TRAF1 transgenic and negative lit-
termates. H-2b mice were infected intravenously with 2000 PFU LCMV
Armstrong strain. On day 8, spleen cells from TRAF1 transgenic (closed
symbols) and TRAF1 negative (open symbols) littermates were tested on
GP33-labeled (squares) and not labeled (circles) EL4 target cells in 5-h
51Cr-release assays as described in Materials and Methods. (B and C) Im-
paired deletion of peptide-specific T cells in TRAF1 transgenic mice. For
induction of tolerance, H-2b control (B) or TRAF1 transgenic (C) litter-
mates were injected intraperitoneally on days 0, 3, and 6 with 500 mg
GP33 peptide (squares) or buffered salt solution (circles) in IFA as described
in Materials and Methods. The mice were infected on day 16 and tested
on day 24 as in (A). One of three representative experiments is shown.1782 Regulation of T Cell Apoptosis by TNF Receptor-associated Factor 1
apoptosis (44–47). It is not likely that TRAF1 overexpres-
sion affected NF-kB–mediated anti-apoptotic signals be-
cause it does not influence the TNFR-mediated NF-kB
activation in transient transfection experiments (34–36) and
also in activated T cells from TRAF1 transgenic mice (data
not shown). One plausible mechanism is that TRAF1
overexpression may increase the recruitment of anti-apop-
totic protein(s) such as c-IAPs to the TNFR2 signaling
complex (37). Another possibility is that TRAF1 overex-
pression may inhibit the recruitment or aggregation of pro-
apoptotic signal transducers to the TNFR2 signaling com-
plex. It is also possible that TRAF1 may mediate an as yet
to be determined anti-apoptotic signal during antigen-induced
cell death of mature T cells. This anti-apoptotic property of
TRAF1 may contribute to cell transformation by LMP
protein of EBV, which triggers aggregation of several TRAF
proteins, including TRAF1 (30).
In addition to establishing that TRAF1 is a component
of the TNFR-proximal signaling intermediate involved in
the regulation of apoptosis, our results also provide in vivo
evidence supporting the postulate that TRAF proteins are
likely to exert pleiotropic signals (cell proliferation or apop-
tosis) depending on the various combination of TRAF
proteins in a given cell type (25, 37). Future identification
of downstream signal transducers that bridge TRAF pro-
teins to the apoptotic machinery such as caspases will be
important to understand the detailed molecular mecha-
nisms of how apoptotic signals are regulated by many
members of the TNFR family.
We thank Drs. M. Blackman, J. Lafaille, and W.C. Yen for critically reading the manuscript.
This work was supported in part by Medical Research Council of Canada to P.S. Ohashi and by Howard
Hughes Medical Institute to Y. Choi.
Address correspondence to Yongwon Choi, HHMI, The Rockefeller University, 1230 York Avenue, Box
295, New York, NY 10021.
Received for publication 14 January 1997 and in revised form 10 March 1997.
References
1. Nossal, G.J.V. 1994. Negative selction of lymphocytes. Cell.
76:229–239.
2. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tol-
erance by clonal elimination in the thymus. Cell. 49:273–280.
3. Murphy, K.M., A.B. Heimberger, and D.Y. Loh. 1990. In-
duction by antigen of intrathymic apoptosis of CD41CD81
TCRlo thymocytes in vivo. Science (Wash. DC). 250:1720–
1723.
4. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic toler-
ance of mature T cells: clonal elimination as a consequence of
immunity. Cell. 63:1249–1256.
5. Russell, J.H., C.L. White, D.Y. Loh, and P. Meleedy-Rey.
1991. Receptor-stimulated death pathway is opened by anti-
gen in mature T cells. Proc. Natl. Acad. Sci. USA. 88:2151–
2155.
6. Lenardo, M.J. 1991. Interleukin-2 programs mouse ab T
lymphocytes for apoptosis. Nature (Lond.). 353:858–861.
7. Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF
receptor superfamily of cellular and viral proteins: activation,
costimulation, and death. Cell. 76:959–962.
8. Penninger, J.M., and T.W. Mak. 1994. Signal transduction,
mitotic catastrophes, and death in T-cell development. Immu-
nol. Rev. 142:230–272.
9. Nagata, S., and P. Golstein. 1995. The Fas death factor. Sci-
ence (Wash. DC). 267:1449–1456.
10. Singer, G.G., and A.K. Abas. 1994. The Fas antigen is in-
volved in peripheral but not thymic deletion of T lympho-
cytes in T cell receptor transgenic mice. Immunity. 1:365–371.
11. Sytwu, H.-K., R.S. Libau, and H.O. McDevitt. 1996. The
roles of Fas/APO-1(CD95) and TNF in antigen-induced
programmed cell death in T cell receptor transgenic mice.
Immunity. 5:17–30.
12. Zheng, L., G. Fisher, R.E. Miller, J. Peschon, D.H. Lynch,
and M.J. Lenardo. 1995. Induction of apoptosis in mature T
cells by tumor necrosis factor. Nature (Lond.). 377:348–351.
13. Speiser, D.E., E. Sebzda, T. Ohteki, M.F. Bachmann, K.
Pfeffer, T.W. Mak, and P.S. Ohashi. 1996. TNF receptor
p55 mediates in vivo deletion of peripheral cytotoxic T lym-
phocytes. Eur. J. Immunol. 26:3055–3060.
14. Chinnaiyan, A.M., K. O’Rourke, M. Tewari, and V.M.
Dixit. 1995. FADD, a novel death domain–containing protein,
interacts with the death domain of Fas and initiates apoptosis.
Cell. 81:505–512.
15. Boldin, M.P., E.E. Varfolomeev, Z. Pancer, I.L. Mett, J.H.
Camonis, and D. Wallach. 1995. A novel protein that inter-
acts with the death domain of Fas/APO1 contains a sequence
motif related to the death domain. J. Biol. Chem. 270:7795–
7798.
16. Hsu, H., J. Huang, H.-B. Shu, V. Baichwal, and D.V. Goed-
del. 1996. TNF-dependent recruitment of the protein kinase
RIP to the TNF receptor-1 signaling complex. Immunity. 4:
387–396.
17. Hsu, H., J. Xiong, and D.V. Goeddel. 1995. The TNF re-
ceptor 1-associated protein TRADD signals cell death and
NF-kB activation. Cell. 81:495–504.
18. Hsu, H., H.B. Shu, M.-G. Pan, and D.V. Goeddel. 1996.
TRADD–TRAF2 and TRADD–FADD interactions define
two distinct TNF receptor 1 signal transduction pathway.
Cell. 84:299–308.
19. Stanger, B.Z., P. Leder, T.-H. Lee, E. Kim, and B. Seed.
1995. RIP: A novel protein containing a death domian that
ineracts with Fas/APO-1(CD95) in yeast and causes cell
death.  Cell. 81:513–523.
20. Itoh, N., and S. Nagata. 1993. A novel protein domain re-1783 Speiser et al.
quired for apoptosis. J. Biol. Chem. 268:10932–10937.
21. Tartaglia, L.A., T.M. Ayres, G.H.W. Wong, and D.V.
Goeddel. 1993. A novel domain within the 55 kd TNF re-
ceptor signals cell death. Cell. 74:845–853.
22. Boldin, M.P., T.M. Goncharov, Y.V. Golstev, and D.
Wallach. 1996. Involvement of MACH, a novel MORT1/
FADD-interacting protease in Fas/APO-1 and TNF recep-
tor-induced cell death. Cell. 81:803–815.
23. Muzio, M., A.M. Cinnaiyan, F.C. Kischkel, K. O’Rourke,
A. Shevchenko, J. Ni, C. Scaffidi, J.D. Brentz, M. Zhang, R.
Gentz et al. 1996. FLICE, a novel FADD-homologous ICE/
CED-3–like protease, is recruited to the CD95 (Fas/APO-1)
death-inducing signaling complex. Cell. 85:817–827.
24. Rothe, M., S.C. Wong, W.J. Henzel, and D.V. Goeddel.
1994. A novel family of putative signal transducers associated
with the cytoplasmic domain of the 75 kDa tumor necrosis
factor receptor. Cell. 78:681–692.
25. Cheng, G., A.M. Cleary, Z.-S. Ye, D.I. Hong, S. Lederman,
and D. Baltimore. 1995. Involvement of CRAF1, a relative
of TRAF, in CD40 signaling. Science (Wash. DC). 267:1494–
1498.
26. Nakano, H., H. Oshima, W. Chung, L. Williams-Abbott,
C.F. Ware, H. Yagita, and K. Okumura. 1996. TRAF5, an
activator of NF-kB and putative signal transducer for the
lymphotoxin-beta receptor. J. Biol. Chem. 271:14661–14664.
27. Sato, T., S. Irie, and J.C. Reed. 1995. A novel member of the
TRAF family of putative signal transducing proteins binds to
the cytosolic domain of CD40. FEBS Lett. 358:113–118.
28. Regnier, C.H., C. Tomasetto, C. Moog-Lutz, M.P. Che-
nard, C. Wendling, P. Basset, and M.C. Rio. 1995. Presence
of a new conserved domain in CART1, a novel member of
the tumor necrosis factor receptor–associated protein family,
which is expressed in breast carcinoma. J. Biol. Chem. 270:
25715–25721.
29. Hu, H.M., K. O’Rourke, M.S. Boguski, and V.M. Dixit.
1994. A novel RING finger protein interacts with the cyto-
plasmic domain of CD40. J. Biol. Chem. 269:30069–30072.
30. Moisalos, G., M. Birkenbach, R. Yalamanchili, T. VanArs-
dale, C. Ware, and E. Kieff. 1995. The Epstein–Barr virus trans-
forming protein LMP1 engages signal proteins for the tumor
necrosis factor receptor family. Cell. 80:389–399.
31. Gedrich, R.W., M.C. Gilfillan, C.S. Duckett, J.L. Van Don-
gen, and C.B. Thompson. 1996. CD30 contains two binding
sites with different specificities for members of the tumor ne-
crosis factor receptor–associated factor family of signal trans-
ducing proteins. J. Biol. Chem. 271:12852–12858.
32. Lee, S.Y., C.G. Park, and Y. Choi. 1996. T cell receptor–
dependent cell death of T cell hybridomas mediated by the
CD30 cytoplasmic domain in association with tumor necrosis
factor receptor–associated factors. J. Exp. Med. 183:669–674.
33. Song, H.Y., and D.B. Donner. 1995. Association of a RING
finger protein with the cytoplasmic domain of the human
type-2 tumor necrosis factor. Biochem. J. 809:825–829.
34. Rothe, M., V. Sarma, V.M. Dixit, and D.V. Goeddel. 1995.
TRAF2-mediated activation of NF-kB by TNF receptor 2
and CD40. Science (Wash. DC). 269:1424–1427.
35. Cheng, G., and D. Baltimore. 1996. TANK, a co-inducer
with TRAF2 of TNF- and CD40L-mediated NF-kB activa-
tion. Genes Dev. 10:963–973.
36. Lee, S.Y., S.Y. Lee, G. Kandala, M.-L. Liou, H.-C. Liou,
and Y. Choi. 1996. CD30–TRAF interaction; NF-kB acti-
vation and binding specificity. Proc. Natl. Acad. Sci. USA. 93:
9699–9703.
37. Rothe, M., M.-G. Pan, W.J. Henzel, T.M. Ayres, and D.V.
Goeddel. 1995. The TNFR2–TRAF signaling complex con-
tains two novel proteins related to baculoviral inhibitor of apop-
tosis proteins. Cell. 83:1243–1252.
38. Pircher, H., K. Burki, R. Lang, H. Hengartner, and R.M.
Zinkernagel. 1989. Tolerance induction in double specific
T-cell receptor transgenic mice varies with antigen. Nature
(Lond.). 342:559–561.
39. Pircher, H., T.W. Mak, R. Lang, W. Ballhausen, E. Ruedi,
H. Hengartner, R.M. Zinkernagel, and K. Burki. 1989. T
cell tolerance to Mlsa encoded antigens in T cell receptor
Vbeta 8.1 chain transgenic mice. EMBO (Eur. Mol. Biol. Or-
gan.) J. 8:719–727.
40. Kyburz, D., P. Aichele, D.E. Speiser, H. Hengartner, R.M.
Zinkernagel, and H. Pircher. 1993. T cell immunity after a
viral infection versus T cell tolerance induced by soluble viral
peptides. Eur. J. Immunol. 23:1956–1962.
41. Aichele, P., K. Brduscha-Riem, R.M. Zinkernagel, H. Hen-
gartner, and H. Pircher. 1995. T cell priming versus T cell
tolerance induced by synthetic peptides. J. Exp. Med. 182:
261–266.
42. Moskophidis, D., F. Lechner, H. Pircher, and R.M. Zinker-
nagel. 1993. Virus persistence in acutely infected immuno-
competent mice by exhaustion of antiviral cytotoxic effector
T cells. Nature (Lond.). 362:758–761.
43. Vella, A.T., J.E. McCormack, P.S. Linsley, J.W. Kappler, and
P. Marrack. 1995. Lipopolysaccharide interferes with the in-
duction of peripheral T cell death. Immunity. 2:261–270.
44. Beg, A.A., and D. Baltimore. 1996. An essential role for NF-
kB in preventing TNF-a–induced cell death. Science (Wash.
DC). 274:782–784.
45. Wang, C.-Y., M.W. Mayo, and J. Baldwin A.S. 1996. TNF-
and cancer therapy–induced apoptosis: potentiation by inhi-
bition of NF-kB. Science (Wash. DC). 274:784–787.
46. Van Antwerp, D.J., S.J. Martin, T. Kafri, D.R. Green, and
I.M. Verma. 1996. Suppression of TNF-a–induced apoptosis
by NF-kB. Science (Wash. DC). 274:787–789.
47. Liu, Z.-G., H. Hsu, D.V. Goeddel, and M. Karin. 1996. Dis-
section of TNF receptor 1 effector functions: JNK activation
is not linked to apoptosis while NF-kB activation prevents
cell death. Cell. 87:565–576.